Cargando…

Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential

INTRODUCTION: Triple-negative breast cancer (TNBC) is a subtype of highly malignant breast cancer with poor prognosis. TNBC is not amenable to endocrine therapy and often exhibit resistance to current chemotherapeutic agents, therefore, further understanding of the biological properties of these can...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelicano, Hélène, Zhang, Wan, Liu, Jinyun, Hammoudi, Naima, Dai, Jiale, Xu, Rui-Hua, Pusztai, Lajos, Huang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303115/
https://www.ncbi.nlm.nih.gov/pubmed/25209360
http://dx.doi.org/10.1186/s13058-014-0434-6
_version_ 1782353887131336704
author Pelicano, Hélène
Zhang, Wan
Liu, Jinyun
Hammoudi, Naima
Dai, Jiale
Xu, Rui-Hua
Pusztai, Lajos
Huang, Peng
author_facet Pelicano, Hélène
Zhang, Wan
Liu, Jinyun
Hammoudi, Naima
Dai, Jiale
Xu, Rui-Hua
Pusztai, Lajos
Huang, Peng
author_sort Pelicano, Hélène
collection PubMed
description INTRODUCTION: Triple-negative breast cancer (TNBC) is a subtype of highly malignant breast cancer with poor prognosis. TNBC is not amenable to endocrine therapy and often exhibit resistance to current chemotherapeutic agents, therefore, further understanding of the biological properties of these cancer cells and development of effective therapeutic approaches are urgently needed. METHODS: We first investigated the metabolic alterations in TNBC cells in comparison with other subtypes of breast cancer cells using molecular and metabolic analyses. We further demonstrated that targeting these alterations using specific inhibitors and siRNA approach could render TNBC cells more sensitive to cell death compared to other breast cancer subtypes. RESULTS: We found that TNBC cells compared to estrogen receptor (ER) positive cells possess special metabolic characteristics manifested by high glucose uptake, increased lactate production, and low mitochondrial respiration which is correlated with attenuation of mTOR pathway and decreased expression of p70S6K. Re-expression of p70S6K in TNBC cells reverses their glycolytic phenotype to an active oxidative phosphorylation (OXPHOS) state, while knockdown of p70S6K in ER positive cells leads to suppression of mitochondrial OXPHOS. Furthermore, lower OXPHOS activity in TNBC cells renders them highly dependent on glycolysis and the inhibition of glycolysis is highly effective in targeting TNBC cells despite their resistance to other anticancer agents. CONCLUSIONS: Our study shows that TNBC cells have profound metabolic alterations characterized by decreased mitochondrial respiration and increased glycolysis. Due to their impaired mitochondrial function, TNBC cells are highly sensitive to glycolytic inhibition, suggesting that such metabolic intervention may be an effective therapeutic strategy for this subtype of breast cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0434-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4303115
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43031152015-01-23 Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential Pelicano, Hélène Zhang, Wan Liu, Jinyun Hammoudi, Naima Dai, Jiale Xu, Rui-Hua Pusztai, Lajos Huang, Peng Breast Cancer Res Research Article INTRODUCTION: Triple-negative breast cancer (TNBC) is a subtype of highly malignant breast cancer with poor prognosis. TNBC is not amenable to endocrine therapy and often exhibit resistance to current chemotherapeutic agents, therefore, further understanding of the biological properties of these cancer cells and development of effective therapeutic approaches are urgently needed. METHODS: We first investigated the metabolic alterations in TNBC cells in comparison with other subtypes of breast cancer cells using molecular and metabolic analyses. We further demonstrated that targeting these alterations using specific inhibitors and siRNA approach could render TNBC cells more sensitive to cell death compared to other breast cancer subtypes. RESULTS: We found that TNBC cells compared to estrogen receptor (ER) positive cells possess special metabolic characteristics manifested by high glucose uptake, increased lactate production, and low mitochondrial respiration which is correlated with attenuation of mTOR pathway and decreased expression of p70S6K. Re-expression of p70S6K in TNBC cells reverses their glycolytic phenotype to an active oxidative phosphorylation (OXPHOS) state, while knockdown of p70S6K in ER positive cells leads to suppression of mitochondrial OXPHOS. Furthermore, lower OXPHOS activity in TNBC cells renders them highly dependent on glycolysis and the inhibition of glycolysis is highly effective in targeting TNBC cells despite their resistance to other anticancer agents. CONCLUSIONS: Our study shows that TNBC cells have profound metabolic alterations characterized by decreased mitochondrial respiration and increased glycolysis. Due to their impaired mitochondrial function, TNBC cells are highly sensitive to glycolytic inhibition, suggesting that such metabolic intervention may be an effective therapeutic strategy for this subtype of breast cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0434-6) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-11 2014 /pmc/articles/PMC4303115/ /pubmed/25209360 http://dx.doi.org/10.1186/s13058-014-0434-6 Text en © Pelicano et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unre stricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pelicano, Hélène
Zhang, Wan
Liu, Jinyun
Hammoudi, Naima
Dai, Jiale
Xu, Rui-Hua
Pusztai, Lajos
Huang, Peng
Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
title Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
title_full Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
title_fullStr Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
title_full_unstemmed Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
title_short Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
title_sort mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mtor pathway and therapeutic potential
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303115/
https://www.ncbi.nlm.nih.gov/pubmed/25209360
http://dx.doi.org/10.1186/s13058-014-0434-6
work_keys_str_mv AT pelicanohelene mitochondrialdysfunctioninsometriplenegativebreastcancercelllinesroleofmtorpathwayandtherapeuticpotential
AT zhangwan mitochondrialdysfunctioninsometriplenegativebreastcancercelllinesroleofmtorpathwayandtherapeuticpotential
AT liujinyun mitochondrialdysfunctioninsometriplenegativebreastcancercelllinesroleofmtorpathwayandtherapeuticpotential
AT hammoudinaima mitochondrialdysfunctioninsometriplenegativebreastcancercelllinesroleofmtorpathwayandtherapeuticpotential
AT daijiale mitochondrialdysfunctioninsometriplenegativebreastcancercelllinesroleofmtorpathwayandtherapeuticpotential
AT xuruihua mitochondrialdysfunctioninsometriplenegativebreastcancercelllinesroleofmtorpathwayandtherapeuticpotential
AT pusztailajos mitochondrialdysfunctioninsometriplenegativebreastcancercelllinesroleofmtorpathwayandtherapeuticpotential
AT huangpeng mitochondrialdysfunctioninsometriplenegativebreastcancercelllinesroleofmtorpathwayandtherapeuticpotential